🚀 VC round data is live in beta, check it out!
Medacta Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Medacta Group and similar public comparables like Merit Medical Systems, Minimed Group, iRhythm Holdings, TransMedics and more.
Medacta Group Overview
About Medacta Group
Medacta Group SA is involved in developing, manufacturing and distributing orthopedic and neurosurgical medical devices. The company offers solutions for Hip, Knee, Shoulder and Spine. The majority of the company's revenue is generated from Europe, Middle East, and Africa (EMEA) and the rest from other regions.
Founded
1999
HQ
Employees
1.9K
Website
Financials (LTM)
EV
$4B
Medacta Group Financials
Medacta Group reported last 12-month revenue of $819M and EBITDA of $230M.
In the same LTM period, Medacta Group generated $230M in EBITDA and $113M in net income.
Revenue (LTM)
Medacta Group P&L
In the most recent fiscal year, Medacta Group reported revenue of $805M and EBITDA of $231M.
Medacta Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $819M | XXX | $805M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $540M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $230M | XXX | $231M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $113M | XXX | $112M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | — | — | $200M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Medacta Group Stock Performance
Medacta Group has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Medacta Group's stock price is $208.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 0.2% | XXX | XXX | XXX | $5.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMedacta Group Valuation Multiples
Medacta Group trades at 5.4x EV/Revenue multiple, and 19.2x EV/EBITDA.
EV / Revenue (LTM)
Medacta Group Financial Valuation Multiples
As of April 19, 2026, Medacta Group has market cap of $4B and EV of $4B.
Equity research analysts estimate Medacta Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medacta Group has a P/E ratio of 36.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 19.2x | XXX | 19.1x | XXX | XXX | XXX |
| EV/EBIT | 31.9x | XXX | 33.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.2x | XXX | XXX | XXX |
| P/E | 36.9x | XXX | 37.0x | XXX | XXX | XXX |
| EV/FCF | 156.7x | XXX | 180.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Medacta Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Medacta Group Margins & Growth Rates
Medacta Group's revenue in the last 12 month grew by 14%.
Medacta Group's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Medacta Group's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medacta Group's rule of X is 59% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Medacta Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 34% | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Medacta Group Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Merit Medical Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Minimed Group | XXX | XXX | XXX | XXX | XXX | XXX |
| iRhythm Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| TransMedics | XXX | XXX | XXX | XXX | XXX | XXX |
| Renishaw | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medacta Group M&A Activity
Medacta Group acquired XXX companies to date.
Last acquisition by Medacta Group was on XXXXXXXX, XXXXX. Medacta Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Medacta Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMedacta Group Investment Activity
Medacta Group invested in XXX companies to date.
Medacta Group made its latest investment on XXXXXXXX, XXXXX. Medacta Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Medacta Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Medacta Group
| When was Medacta Group founded? | Medacta Group was founded in 1999. |
| Where is Medacta Group headquartered? | Medacta Group is headquartered in Switzerland. |
| How many employees does Medacta Group have? | As of today, Medacta Group has over 1K employees. |
| Is Medacta Group publicly listed? | Yes, Medacta Group is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Medacta Group? | Medacta Group trades under MOVE ticker. |
| When did Medacta Group go public? | Medacta Group went public in 2019. |
| Who are competitors of Medacta Group? | Medacta Group main competitors are Merit Medical Systems, Minimed Group, iRhythm Holdings, TransMedics. |
| What is the current market cap of Medacta Group? | Medacta Group's current market cap is $4B. |
| What is the current revenue of Medacta Group? | Medacta Group's last 12 months revenue is $819M. |
| What is the current revenue growth of Medacta Group? | Medacta Group revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Medacta Group? | Current revenue multiple of Medacta Group is 5.4x. |
| Is Medacta Group profitable? | Yes, Medacta Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medacta Group? | Medacta Group's last 12 months EBITDA is $230M. |
| What is Medacta Group's EBITDA margin? | Medacta Group's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Medacta Group? | Current EBITDA multiple of Medacta Group is 19.2x. |
| What is the current FCF of Medacta Group? | Medacta Group's last 12 months FCF is $28M. |
| What is Medacta Group's FCF margin? | Medacta Group's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Medacta Group? | Current FCF multiple of Medacta Group is 156.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.